<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232869</url>
  </required_header>
  <id_info>
    <org_study_id>EE00-02</org_study_id>
    <nct_id>NCT00232869</nct_id>
  </id_info>
  <brief_title>A Study of the SMART Stent in the Treatment SFA Disease.</brief_title>
  <acronym>SIROCCO</acronym>
  <official_title>A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and performance of the sirolimus
      coated Cordis SMART™ nitinol self expandable stent device and its delivery system in the
      treatment of obstructive superficial femoral artery (SFA) disease in reducing percent
      in-stent mean lumen diameter stenosis in de novo or restenotic native lesions as compared to
      the uncoated SMART™ stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, randomized, double blind, two-arm feasibility study
      evaluating the safety and performance of the sirolimus coated Cordis SMART™ nitinol
      self-expanding stent and delivery system as compared to the uncoated SMART™ stent and
      delivery system. It is anticipated that a total of 90 patients will be entered into the
      study. Patients will be randomized on a 1:1 basis of coated to uncoated stents.

      Ninety (90) patients with de novo or restenotic native SFA lesions will be randomized to the
      Sirolimus Coated SMART™ nitinol self-expanding stent or to the uncoated (bare) SMART™ stent.

      Patients will be followed for 24 months post-procedure, with all patients having duplex
      ultrasound and clinical assessments at discharge, 1, 6, 9, 18 and 24 months, angiography at 6
      six months and plain X-ray at 18 months. This study will be conducted at nine investigational
      sites. (Protocol was amended where 56 additional patients were recruited and followed for up
      to 5 years.)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent mean lumen diameter percent stenosis via quantitative angiography.</measure>
    <time_frame>6 months.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SMART™ bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting stent</intervention_name>
    <description>Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bare-metal stent</intervention_name>
    <description>SMART™ bare-metal stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. One superficial femoral artery presenting &gt; 70% stenosis(es) or total occlusion

          2. Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3 or 4)

        Exclusion Criteria:

          1. Tissue loss due to ischemic disease (Rutherford category 5 or 6).

          2. Tandem lesion requiring non overlapping stents;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan H Duda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tübingen - Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tübingen</city>
        <zip>72070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006 Dec;13(6):701-10.</citation>
    <PMID>17154704</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

